Cytokinetics/ US23282W6057 /
2024-07-26 9:59:47 PM | Chg. +1.21 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
59.68USD | +2.07% | 42,183 Turnover: 2.52 mill. |
-Bid Size: - | -Ask Size: - | 61.10 | 58.64 |
GlobeNewswire
06-17
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
GlobeNewswire
05-22
Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire
05-22
Cytokinetics and Royalty Pharma Announce Expanded Strategic Funding Collaboration Totaling Up to $57...
GlobeNewswire
05-17
Cytokinetics Hosts Muscle Biology-Focused Research Symposium: Contemporary Landscapes in Muscle Biol...
GlobeNewswire
05-15
Cytokinetics Announces Five Presentations Related to Aficamten at the European Society of Cardiology...
GlobeNewswire
05-13
Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Se...
GlobeNewswire
05-13
Cytokinetics Announces Additional Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial...
GlobeNewswire
05-08
Cytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population ...
GlobeNewswire
04-29
Cytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-...
GlobeNewswire
04-10
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at t...
GlobeNewswire
04-05
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Stu...
GlobeNewswire
04-05
Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Stu...